Personal information

Emails & domains

Verified email addresses

Verified email domains

Activities

Collapse all

Employment (1)

Università degli Studi di Palermo: Palermo, Sicilia, IT

2016-11-01 to 2019-10-01 | dottorato di ricerca in " Oncologia e Chirurgia Sperimentali Internazionali" (Dipartimento delle Discipline Chirurgiche Oncologiche e Stomatologiche )
Employment
Source: Self-asserted source
Angela Listi

Works (14)

Data from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring <i>HRR</i> Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

2024-03-01 | Preprint
DOI: 10.1158/1078-0432.c.7100048.v1
Contributors: Francesco Passiglia; Luisella Righi; Paolo Bironzo; Angela Listì; Giovanni Farinea; Enrica Capelletto; Silvia Novello; Alessandra Merlini; Giorgio V. Scagliotti
Source: check_circle
Crossref

Data from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring <i>HRR</i> Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

2024-03-01 | Preprint
DOI: 10.1158/1078-0432.c.7100048
Contributors: Francesco Passiglia; Luisella Righi; Paolo Bironzo; Angela Listì; Giovanni Farinea; Enrica Capelletto; Silvia Novello; Alessandra Merlini; Giorgio V. Scagliotti
Source: check_circle
Crossref

Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

Clinical Cancer Research
2024-03-01 | Journal article
DOI: 10.1158/1078-0432.CCR-23-2431
Contributors: Francesco Passiglia; Luisella Righi; Paolo Bironzo; Angela Listì; Giovanni Farinea; Enrica Capelletto; Silvia Novello; Alessandra Merlini; Giorgio V. Scagliotti
Source: check_circle
Crossref

Supplementary Figure 1 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring <i>HRR</i> Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

2024-03-01 | Preprint
DOI: 10.1158/1078-0432.25324520
Contributors: Francesco Passiglia; Luisella Righi; Paolo Bironzo; Angela Listì; Giovanni Farinea; Enrica Capelletto; Silvia Novello; Alessandra Merlini; Giorgio V. Scagliotti
Source: check_circle
Crossref

Supplementary Figure 1 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring <i>HRR</i> Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

2024-03-01 | Preprint
DOI: 10.1158/1078-0432.25324520.v1
Contributors: Francesco Passiglia; Luisella Righi; Paolo Bironzo; Angela Listì; Giovanni Farinea; Enrica Capelletto; Silvia Novello; Alessandra Merlini; Giorgio V. Scagliotti
Source: check_circle
Crossref

Supplementary Figure 2 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring <i>HRR</i> Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

2024-03-01 | Preprint
DOI: 10.1158/1078-0432.25324517.v1
Contributors: Francesco Passiglia; Luisella Righi; Paolo Bironzo; Angela Listì; Giovanni Farinea; Enrica Capelletto; Silvia Novello; Alessandra Merlini; Giorgio V. Scagliotti
Source: check_circle
Crossref

Supplementary Figure 2 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring <i>HRR</i> Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

2024-03-01 | Preprint
DOI: 10.1158/1078-0432.25324517
Contributors: Francesco Passiglia; Luisella Righi; Paolo Bironzo; Angela Listì; Giovanni Farinea; Enrica Capelletto; Silvia Novello; Alessandra Merlini; Giorgio V. Scagliotti
Source: check_circle
Crossref

Supplementary Figure 3 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring <i>HRR</i> Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

2024-03-01 | Preprint
DOI: 10.1158/1078-0432.25324514
Contributors: Francesco Passiglia; Luisella Righi; Paolo Bironzo; Angela Listì; Giovanni Farinea; Enrica Capelletto; Silvia Novello; Alessandra Merlini; Giorgio V. Scagliotti
Source: check_circle
Crossref

Supplementary Figure 3 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring <i>HRR</i> Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

2024-03-01 | Preprint
DOI: 10.1158/1078-0432.25324514.v1
Contributors: Francesco Passiglia; Luisella Righi; Paolo Bironzo; Angela Listì; Giovanni Farinea; Enrica Capelletto; Silvia Novello; Alessandra Merlini; Giorgio V. Scagliotti
Source: check_circle
Crossref

Supplementary Table 1 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring <i>HRR</i> Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

2024-03-01 | Preprint
DOI: 10.1158/1078-0432.25324511
Contributors: Francesco Passiglia; Luisella Righi; Paolo Bironzo; Angela Listì; Giovanni Farinea; Enrica Capelletto; Silvia Novello; Alessandra Merlini; Giorgio V. Scagliotti
Source: check_circle
Crossref

Supplementary Table 1 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring <i>HRR</i> Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

2024-03-01 | Preprint
DOI: 10.1158/1078-0432.25324511.v1
Contributors: Francesco Passiglia; Luisella Righi; Paolo Bironzo; Angela Listì; Giovanni Farinea; Enrica Capelletto; Silvia Novello; Alessandra Merlini; Giorgio V. Scagliotti
Source: check_circle
Crossref

Supplementary Table 2 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring <i>HRR</i> Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

2024-03-01 | Preprint
DOI: 10.1158/1078-0432.25324508
Contributors: Francesco Passiglia; Luisella Righi; Paolo Bironzo; Angela Listì; Giovanni Farinea; Enrica Capelletto; Silvia Novello; Alessandra Merlini; Giorgio V. Scagliotti
Source: check_circle
Crossref

Supplementary Table 2 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring <i>HRR</i> Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

2024-03-01 | Preprint
DOI: 10.1158/1078-0432.25324508.v1
Contributors: Francesco Passiglia; Luisella Righi; Paolo Bironzo; Angela Listì; Giovanni Farinea; Enrica Capelletto; Silvia Novello; Alessandra Merlini; Giorgio V. Scagliotti
Source: check_circle
Crossref

Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma

Cancers
2021-05 | Journal article | Author
DOI: 10.3390/cancers13112564
Contributors: Francesca Napoli; Angela Listi; Vanessa Zambelli; Gianluca Witel; Paolo Bironzo; Mauro Papotti; Marco Volante; Giorgio Scagliotti; Luisella Righi
Source: check_circle
Multidisciplinary Digital Publishing Institute
grade
Preferred source (of 2)‎

Peer review (1 review for 1 publication/grant)

Review activity for British journal of cancer. (1)
How many people are using ORCID?